<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04137588</url>
  </required_header>
  <id_info>
    <org_study_id>20191023</org_study_id>
    <nct_id>NCT04137588</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer</brief_title>
  <official_title>A Prospective of Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the efficacy and safety of Use of Platinum Based&#xD;
      Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With&#xD;
      Advanced Non-squamous Non-small Cell Lung Cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 3, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>one year</time_frame>
    <description>ORR of treatment</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Advanced Non-squamous Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>antiangiogenesis 7.5mg/Kg q3w+pemetrexed 500mg/m2 q3w+ platinum 75mg/m2 q3w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>immune checkpoint inhibitors 200mg q3w+pemetrexed 500mg/m2 q3w+platinum 75mg/m2 q3w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <description>antiangiogenesis 7.5mg/Kg q3w+immune checkpoint inhibitors 200mg q3w+pemetrexed 500mg/m2 q3w+platinum 75mg/m2 q3w</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiangiogenesis Agents</intervention_name>
    <description>antiangiogenesis agents plus chemotherapy as first line treatment</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immune checkpoint inhibitor</intervention_name>
    <description>immune checkpoint inhibitor plus chemotherapy as first line treatment</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Males and females, 18-75 years of age, non squamous non-small cell lung cancer, wild type&#xD;
        genotype&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily sign informed consent;&#xD;
&#xD;
          2. Non-squamous non-small cell lung cancer, newly diagnosed or previously not treated&#xD;
             with systemic chemotherapy and / or epidermal growth factor receptor (EGFR) tyrosine&#xD;
             kinase inhibitors treatment;&#xD;
&#xD;
          3. Aged 18-75 years;&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) score ≤ 2;&#xD;
&#xD;
          5. Survival is expected to exceed 12 weeks ;&#xD;
&#xD;
          6. Patients had a wild-type genotype (WT population; patients with EGFR or ALK genetic&#xD;
             alterations were excluded)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        If any of the following criteria is met, the subject shall be excluded:&#xD;
&#xD;
          1. Squamous cell carcinoma (including adenosquamous carcinoma) and small cell lung cancer&#xD;
             (including small cell carcinoma and non-small cell mixed lung cancer);&#xD;
&#xD;
          2. In the past 2 weeks, there have been systematic anti-tumor treatment including&#xD;
             chemotherapy (including thoracic chemotherapy), radiotherapy (excluding radiotherapy&#xD;
             of metastatic lesions outside the thoracic radiation field), targeted therapy,&#xD;
             immunotherapy and biotherapy;&#xD;
&#xD;
          3. The subject had received anti-vascular endothelial growth factor (VEGF) small molecule&#xD;
             tyrosine kinase inhibitors or monoclonal antibodies in the past 4 weeks;&#xD;
&#xD;
          4. Laboratory results:&#xD;
&#xD;
               -  White blood cell count &lt;3 × 109 / L, neutrophil count &lt;1.5 × 109 / L, platelet&#xD;
                  &lt;75 × 109 / L, or hemoglobin &lt;8g / dL;&#xD;
&#xD;
               -  Coagulation abnormalities (INR &gt; 1.5 or prothrombin time (PT) &gt; ULN + 4 seconds&#xD;
                  or activated partial thromboplastin time (APTT) &gt; 1.5 ULN), with bleeding&#xD;
                  tendency or being treated with thrombolysis or anticoagulation;&#xD;
&#xD;
               -  Serum total bilirubin ≥1.5 ULN; alanine aminotransferase (ALT) or aspartate&#xD;
                  aminotransferase (AST) ≥ 2.5 ULN in the absence of liver metastases; ALT or AST&#xD;
                  ≥5 ULN in liver metastases;&#xD;
&#xD;
               -  Serum albumin &lt;30g / L;&#xD;
&#xD;
               -  Serum creatinine ≥ 1.5 ULN or creatinine clearance &lt;40ml / min; • Urine routine&#xD;
                  urinary protein ≥ ++, or 24 hours urine protein ≥ 1.0 g;&#xD;
&#xD;
          5. Heart disease with significant clinical symptoms, such as: congestive heart failure,&#xD;
             coronary heart disease with symptom, arrhythmia hardly be controlled by drugs,&#xD;
             myocardial infarction in 6 months, or heart failure;&#xD;
&#xD;
          6. Imaging (CT or MRI) showed a tumor lesion 5 mm away from the large vessels, or the&#xD;
             presence of invasive central vasculature of the central tumor; imaging (CT or MRI)&#xD;
             showed significant cavitation or necrosis of the lung tumor; Other diseases that may&#xD;
             cause haemoptysis;&#xD;
&#xD;
          7. Imaging (CT or chest radiograph) showed significant pneumothorax, fluid pneumothorax;&#xD;
&#xD;
          8. Obvious cough blood in 6 months, or daily hemoptysis amounted to half a teaspoon&#xD;
             (2.5ml) or more;&#xD;
&#xD;
          9. Significant bleeding symptoms or with definite bleeding tendency within 12 months&#xD;
             before randomization, such as gastrointestinal bleeding, hemorrhagic gastric ulcer,&#xD;
             occult blood ++ and above, intracerebral hemorrhage, vasculitis, or with congenital or&#xD;
             acquired coagulopathy disorders;&#xD;
&#xD;
         10. Thrombosis, cancer thrombosis (including arteriovenous thrombosis, tumor thrombus,&#xD;
             pulmonary embolism, transient ischemic attack, etc.) occurred within 12 months;&#xD;
&#xD;
         11. There are gastrointestinal obstruction, peptic ulcer, Crohn's disease, ulcerative&#xD;
             colitis and other gastrointestinal diseases or other diseases may cause&#xD;
             gastrointestinal bleeding or perforation;&#xD;
&#xD;
         12. Severe respiratory diseases, or need long-term oxygen, corticosteroid treatment of&#xD;
             diseases such as chronic obstructive pulmonary disease, interstitial lung disease and&#xD;
             respiratory failure;&#xD;
&#xD;
         13. Patients with uncontrolled central nervous system metastasis;&#xD;
&#xD;
         14. There are serious uncontrolled systemic diseases, such as nephrotic syndrome,&#xD;
             infection, poorly controlled diabetes;&#xD;
&#xD;
         15. Patients with active HIV（human immunodeficiency virus）, HBV（hepatitis B virus）, or&#xD;
             HCV（hepatitis C virus） infection;&#xD;
&#xD;
         16. Patients had undergone surgery (&lt;28 days) or did not heal completely, or had other&#xD;
             unhealed wounds before the study;&#xD;
&#xD;
         17. Patients known to be allergic to bevacizumab or any of the components of the drug;&#xD;
&#xD;
         18. Pregnant or lactating female patients, or unwilling to take contraceptive measures of&#xD;
             reproductive age patients (including men);&#xD;
&#xD;
         19. There is a serious psychological or mental abnormality, or lack of compliance;&#xD;
&#xD;
         20. The investigator determines other circumstances that may affect the conduct of&#xD;
             clinical studies and the determination of findings;&#xD;
&#xD;
         21. Participants with an active, known or suspected autoimmune disease;&#xD;
&#xD;
         22. Participants with a condition requiring systemic treatment with either corticosteroids&#xD;
             or other immunosuppressive medications within 14 days of first treatment;&#xD;
&#xD;
         23. Participants with interstitial lung disease that is symptomatic or may interfere with&#xD;
             the detection or management of suspected drug related pulmonary toxicity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Jian Fang, doctor</last_name>
    <phone>+86-010-88196469</phone>
    <email>bcht2_mj@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jie Zhang, doctor</last_name>
    <phone>+86-010-88196478</phone>
    <email>zhangjie@bjmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jian Fang</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Fang</last_name>
      <phone>+86-010-88196469</phone>
      <email>bcht2_mj@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jie Zhang</last_name>
      <phone>+86-010-88196478</phone>
      <email>zhangjie@bjmu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 22, 2019</study_first_submitted>
  <study_first_submitted_qc>October 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2019</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Jian Fang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
    <mesh_term>Angiogenesis Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

